Results 11 to 20 of about 10,491 (187)

Drug-drug interactions with raltegravir

European Journal of Medical Research, 2009
Objective To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir. Methods A PubMed search was conducted for all published reports up to August 1, 2009 as well as a review of updated European and US ...
Burger David M
doaj   +2 more sources

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy

Infection and Drug Resistance, 2010
Charlotte Charpentier1, Laurence Weiss21Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Université Paris-Diderot, Paris, France; 2Assistance Publique-Hôpitaux de ...
Charlotte Charpentier, Laurence Weiss
doaj   +2 more sources

Dissolution Enhancement of Raltegravir by Hot Melt Extrusion Technique

Iraqi Journal of Pharmaceutical Sciences, 2018
The objective of the study to develop an amorphous solid dispersion for poorly soluble raltegravir by hot melt extrusion (HME) technique. A novel solubility improving agent plasdone  s630 was utilized.
Ahmed S. Abdul Jabbar
doaj   +3 more sources

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Infection and Drug Resistance, 2010
Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj   +1 more source

Long-term efficacy and safety of raltegravir in the management of HIV infection

Infection and Drug Resistance, 2014
Michelle D Liedtke, C Ryan Tomlin, Staci M Lockhart, Misty M Miller, R Chris Rathbun Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Raltegravir is ...
Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC   +4 more
doaj   +1 more source

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Successful Therapeutic Plasma Exchange Treatment After SARS-CoV-2 Infection-A Case Report. [PDF]

Clin Case Rep
This schematic timeline of symptom progression, infectious history, autoantibody dynamics, and therapeutic interventions illustrates the clinical course of our patient with long‐standing ME/CFS, showing initial improvement during Raltegravir therapy, subsequent symptom worsening following SARS‐CoV‐2 infection with rising autoantibody levels, and ...
Ciobanu G, Arn N.
europepmc   +2 more sources

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. [PDF]

HIV Med
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Zhang L, Chen L, Tang J, Liu X, Zheng L, Wang F, Huang X, Cao W, Li T.   +8 more
europepmc   +2 more sources

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir [PDF]

, 2011
The identification of transporters of the HIV integrase inhibitor raltegravir could be a factor in an understanding of the pharmacokinetic-pharmacodynamic relationship and reported drug interactions of raltegravir.
Back, David, David J. Back, Kwan, Wai San, Darren M. Moss, Darren L. Smith, Smith, Darren, Marco Siccardi, Khoo, Saye, Siccardi, Marco, Liptrott, Neill, Saye H. Khoo, Wai San Kwan, Andrew Owen, Owen, Andrew, Moss, Darren, Neill J. Liptrott   +15 more
core   +2 more sources

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith, Dana N Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I Mullins, Papa Salif Sow, Geoffrey S Gottlieb, University of Washington-Dakar HIV-2 Study Group   +10 more
doaj   +1 more source

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP

Annals of Clinical and Translational Neurology, 2021
Objective Human T‐cell lymphotropic virus 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive myelopathy. A high proviral load (PVL) is one of the main risk factors for HAM/TSP.
Yoshimi Enose‐Akahata, Bridgette Jeanne Billioux, Shila Azodi, Jennifer Dwyer, Ashley Vellucci, Nyater Ngouth, Satoshi Nozuma, Raya Massoud, Irene Cortese, Joan Ohayon, Steven Jacobson   +10 more
doaj   +1 more source